Drug Profile
Itacnosertib - Sumitomo Pharma America
Alternative Names: Itacnosertib - Sumitomo Dainippon Pharma Oncology; TP-0184Latest Information Update: 19 Jul 2023
Price :
$50
*
At a glance
- Originator Tolero Pharmaceuticals
- Developer Sumitomo Pharma America
- Class Amines; Antianaemics; Antineoplastics; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action ACVR1 protein inhibitors; Transforming growth factor beta type I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Acute myeloid leukaemia
- Discontinued Anaemia
Most Recent Events
- 30 Mar 2023 Sumitomo Pharma Oncology terminates a phase I/II trial in Anaemia (Treatment-resistant) in USA (PO) due to limitations imposed by the COVID pandemic and the competitive landscape for myelodysplastic syndrome (NCT04623996)
- 10 Dec 2022 Pharmacodynamics data from a preclinical study in Acute myeloid leukemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 24 May 2022 Discontinued - Phase-I/II for Anaemia (Treatment-resistant) in USA (PO) (Sumitomo Pharma pipeline, May 2022)